Surmodics

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Surmodics reports Q1 growth, FDA hurdles, and strategic partnerships

Surmodics navigates FDA challenges with the SurVeil application while focusing on cost-saving measures and revenue growth strategies for fiscal 2023.
The company's strong technology foundation, partnership with Abbott, and customer acceptance of key products position it well for future growth.
Despite challenges in FDA approval and spending reductions, Surmodics remains committed to innovation, regulatory compliance, and strategic partnerships.
Opportunities in product commercialization, revenue growth, and asset preservation offer avenues for overcoming challenges and driving long-term success.

Surmodics reports solid Q2 growth, navigates FDA approvals and revenue challenges

Surmodics shows strong performance in medical device sales and strategic objectives execution.
Challenges include In Vitro Diagnostics revenue decline and revised fiscal guidance.
Opportunities lie in significant sales growth projections and regulatory milestones.
Financial stability maintained through cash utilization plan and spending reduction measures.
Overall, Surmodics navigates growth and challenges with a focus on FDA approvals and revenue growth.

Surmodics excels in Q3 with robust revenue growth and strategic partnerships

Surmodics delivered exceptional Q3 results, driven by strong revenue growth and operational achievements, setting the stage for continued success.
The company's focus on cash flow generation, disciplined expense management, and strategic partnerships with Abbott bode well for future growth and profitability.
While facing challenges such as COVID-related impacts and revenue sharing negotiations, Surmodics remains poised to capitalize on opportunities for growth and innovation.
With a solid financial position, expanded revenue guidance, and readiness to support Abbott's commercial initiatives, Surmodics is well-positioned for a promising future.

Surmodics reports robust Q4 earnings, eyes growth amidst challenges

Surmodics delivered strong financial performance in Q4 2023 and fiscal 2023, driven by revenue growth and operational improvements.
While facing challenges such as competitive dynamics and projected losses in fiscal 2024, the company is well-positioned to capitalize on opportunities.
Strategic achievements, product advancements, and financial stability position Surmodics for continued growth and market success in the coming year.
Emphasis on innovation, market expansion, and cost management will be crucial for Surmodics to navigate challenges and leverage growth opportunities.

Surmodics reports robust Q1 growth, eyes new product launches

Surmodics' Q1 2024 performance reflects strong revenue growth, operational efficiency, and successful product launches, positioning the company for continued success in the medical device and diagnostics markets.
While challenges such as incremental expenses and pricing dynamics exist, Surmodics' focus on innovation, financial discipline, and market responsiveness presents opportunities for sustained growth and competitive advantage.
With a strategic outlook towards driving revenue growth, expanding product offerings, and optimizing expenses, Surmodics aims to navigate challenges and capitalize on opportunities for long-term success and market leadership.

Surmodics reports robust Q2 growth, eyes profitability amid challenges

Surmodics' Q2 2024 performance reflects revenue growth, improved profitability, and product innovation, underpinned by strong R&D focus and strategic partnerships.
While facing challenges in achieving profitability and providing clear guidance for fiscal 2025, the company remains optimistic about growth opportunities and market expansion.
With a focus on enhancing margins, expanding product offerings, and leveraging partnerships, Surmodics is poised for continued growth and innovation in the medical device industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures vascular interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

SurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

SurModics (SRDX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.36 per share. This compares to loss of $0.40 per share a year ago.

SurModics (SRDX) Q2 Earnings and Revenues Top Estimates

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #PressRelease--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024. Second Quarter Fiscal 2024 Financial Summary Total Revenue of $32.0 million, an increase of 18% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”).

Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #EarningsCall--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 1. Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Wednesday, May 1, to discuss the second quarter fiscal 2024 financial results and accomplishments and.

Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know

Inspire Medical Systems Inc

Metals Acquisition Ltd

Telenor ASA

United States Steel

SRDX, X, TELNY, INSP and MTAL have been added to the Zacks Rank #1 (Strong Buy) List on April 9, 2023.

New Strong Buy Stocks for April 9th

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor conferences: The 34th Annual Oppenheimer Healthcare Conference, which is being held virtually from March 12-13, 2024. Management will present on Wednesday, March 13, at 2:00 p.m. Eastern Time. The 23rd Annual Needham Healthcare Conference, whi.

Surmodics to Participate in Upcoming Investor Conferences in March and April

Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust segmental revenues.

Surmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 View

Surmodics, Inc (SRDX) Q1 2024 Earnings Call Transcript

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

SurModics (SRDX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

SurModics (SRDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.50 per share a year ago.

SurModics (SRDX) Reports Break-Even Earnings for Q1

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2023, and updated its financial guidance for fiscal year ending September 30, 2024. First Quarter Fiscal 2024 Financial Summary Total Revenue of $30.6 million, an increase of 23% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”.

Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

Surmodics (SRDX) new addition to its Pounce Thrombectomy Platform is recommended for use in vessels with a diameter between 2 mm and 4 mm for clot removal.

Surmodics' (SRDX) New Device to Boost Its Thrombectomy Platform

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced successful early clinical use of the company's Pounce™ LP (Low Profile) Thrombectomy System. The Pounce LP Thrombectomy System, which received U.S. Food and Drug Administration (FDA) clearance in June 2023, is currently in limited market evaluation (LME), with full commercial launch planned following completion of the LME. Surmodics' Po.

Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 8, at 4 p.m. CT (5 p.m. ET), as a virtual meeting. Sue Knight, Chair of the Board, will lead the meeting, and Gary Maharaj, President and Chief Executive Officer, will provide a brief update on business and key strategic initiatives underway at the Company. To.

Surmodics to Host Virtual Annual Meeting of Shareholders

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first quarter of fiscal year 2024 financial results will be released before the market opens on Thursday, February 1. Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Thursday, February 1, to discuss the first quarter fiscal 2024 financial results and accomplishmen.

Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

SurModics (SRDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

SurModics (SRDX) Soars 6.2%: Is Further Upside Left in the Stock?

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that 24-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon (DCB) was presented at the 50th annual VEITH Symposium in New York, New York. The SWING Trial is a 35-subject prospective, multi-center, single-arm, feasibility study to.

Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the 50th Annual VEITH Symposium in New York, New York. The TRANSCEND trial is a prospective, multi-center, single-blind, randomized, controlled trial to assess the safety and efficacy of the SurVeil™ drug coated bal.

Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the 35th Annual Piper Sandler Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from November 28-30, 2023. Management will present on Tuesday, November 28, at 8:30 a.m. ET (7:30 a.m. CT). A live webcast of the presentation can be accesse.

Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28

Surmodics, Inc. (SRDX) Q4 2023 Earnings Call Transcript

Ligand Pharmaceuticals

Health Care Select Sector SPDR Fund

After impressive quarterly results on Wednesday, here are two highly-ranked Zacks Medical sector stocks that investors may want to consider.

2 Highly Ranked Medical Stocks to Consider After Healthy Quarterly Results

Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust segmental revenues.

Surmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/Y

Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

News for Surmodics Stock (SRDX)